Challenges in Diagnosis of Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2018 May 23

PMID 29785074

Citations 249

Authors

Lulu Zhang

Santosh Sanagapalli

Alina Stoita

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is a growing source of cancer related death, yet has poor survival rates which have not improved in the last few decades. Its high mortality rate is attributed to pancreatic cancer biology, difficulty in early diagnosis and the lack of standardised international guidelines in assessing suspicious pancreatic masses. This review aims to provide an update in the current state of play in pancreatic cancer diagnosis and to evaluate the benefits and limitations of available diagnostic technology. The main modalities discussed are imaging with computed tomography, magnetic resonance imaging, endoscopic ultrasound and positron emission tomography and tissue acquisition with fine needle aspiration. We also review the improvements in the techniques used for tissue acquisition and the opportunity for personalised cancer medicine. Screening of high risk individuals, promising biomarkers and common mimickers of pancreatic cancer are also explored, as well as suggestions for future research directions to allow for earlier detection of pancreatic cancer. Timely and accurate diagnosis of pancreatic cancer can lead to improvements in the current poor outcome of this disease.

Citing Articles

Clinical Utility of Fluorine-Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography in the Evaluation of Pancreatic Ductal Adenocarcinoma: Comparison With Fluorine-Fluorodeoxyglucose Positron Emission....

Lin L, Wang G, Zhang Y, Wang G, Zhao K, Su X MedComm (2020). 2025; 6(3):e70136.

PMID: 40066225 PMC: 11891561. DOI: 10.1002/mco2.70136.

Single-Cell Sequencing and Transcriptome Analysis Explored Changes in Midnolin-Related Immune Microenvironment and Constructed Combined Prognostic Model for Pancreatic Cancer.

Guan X, Xu L, Liu J, Fei H, Wang C J Inflamm Res. 2025; 18:2975-2990.

PMID: 40026303 PMC: 11872096. DOI: 10.2147/JIR.S503326.

Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.

Chen J, Zhang X, Zhang G, Zhu F, Liu W BMC Cancer. 2025; 25(1):295.

PMID: 39972247 PMC: 11837301. DOI: 10.1186/s12885-025-13659-2.

Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.

Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.

PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.

Artificial Intelligence in Pancreatic Imaging: A Systematic Review.

Podina N, Gheorghe E, Constantin A, Cazacu I, Croitoru V, Gheorghe C United European Gastroenterol J. 2025; 13(1):55-77.

PMID: 39865461 PMC: 11866320. DOI: 10.1002/ueg2.12723.

References

Ahn S, Kim M, Choi J, Hong H, Chung Y, Lim J . Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol. 2009; 19(10):2448-55. DOI: 10.1007/s00330-009-1422-6. View

Satoh T, Kikuyama M, Kawaguchi S, Kanemoto H, Muro H, Hanada K . Acute pancreatitis-onset carcinoma in situ of the pancreas with focal fat replacement diagnosed using serial pancreatic-juice aspiration cytologic examination (SPACE). Clin J Gastroenterol. 2017; 10(6):541-545. DOI: 10.1007/s12328-017-0776-6. View

Huang Z, Liu F . Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014; 35(8):7459-65. DOI: 10.1007/s13277-014-1995-9. View

Iglesias-Garcia J, Lindkvist B, Larino-Noia J, Abdulkader-Nallib I, Dominguez-Munoz J . Differential diagnosis of solid pancreatic masses: contrast-enhanced harmonic (CEH-EUS), quantitative-elastography (QE-EUS), or both?. United European Gastroenterol J. 2017; 5(2):236-246. PMC: 5349356. DOI: 10.1177/2050640616640635. View

Paquin S, Gariepy G, Lepanto L, Bourdages R, Raymond G, Sahai A . A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc. 2005; 61(4):610-1. DOI: 10.1016/s0016-5107(05)00082-9. View

Lee T, Kim M, Park D, Seo D, Lee S, Kim J . Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009; 193(2):343-8. DOI: 10.2214/AJR.08.2297. View

Iglesias-Garcia J, Dominguez-Munoz J, Abdulkader I, Larino-Noia J, Eugenyeva E, Lozano-Leon A . Influence of on-site cytopathology evaluation on the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of solid pancreatic masses. Am J Gastroenterol. 2011; 106(9):1705-10. DOI: 10.1038/ajg.2011.119. View

Catenacci D, Chapman C, Xu P, Koons A, Konda V, Siddiqui U . Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015; 149(7):1794-1803.e4. PMC: 4985007. DOI: 10.1053/j.gastro.2015.08.050. View

Iwashita T, Nakai Y, Samarasena J, Park D, Zhang Z, Gu M . High single-pass diagnostic yield of a new 25-gauge core biopsy needle for EUS-guided FNA biopsy in solid pancreatic lesions. Gastrointest Endosc. 2013; 77(6):909-15. DOI: 10.1016/j.gie.2013.01.001. View

10.

Tamm E, Balachandran A, Bhosale P, Katz M, Fleming J, Lee J . Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 2012; 50(3):407-28. DOI: 10.1016/j.rcl.2012.03.008. View

11.

Rachagani S, Macha M, Heimann N, Seshacharyulu P, Haridas D, Chugh S . Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev. 2014; 81:16-33. PMC: 4465296. DOI: 10.1016/j.addr.2014.10.020. View

12.

Stoita A, Penman I, Williams D . Review of screening for pancreatic cancer in high risk individuals. World J Gastroenterol. 2011; 17(19):2365-71. PMC: 3103788. DOI: 10.3748/wjg.v17.i19.2365. View

13.

Treadwell J, Zafar H, Mitchell M, Tipton K, Teitelbaum U, Jue J . Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma: A Meta-Analysis. Pancreas. 2016; 45(6):789-95. DOI: 10.1097/MPA.0000000000000524. View

14.

Ballehaninna U, Chamberlain R . The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012; 3(2):105-19. PMC: 3397644. DOI: 10.3978/j.issn.2078-6891.2011.021. View

15.

Brennan D, Zamboni G, Raptopoulos V, Kruskal J . Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 2007; 27(6):1653-66. DOI: 10.1148/rg.276075034. View

16.

Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M . Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92(11):2076-83. PMC: 2361795. DOI: 10.1038/sj.bjc.6602619. View

17.

Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M . CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009; 198(3):333-9. DOI: 10.1016/j.amjsurg.2008.12.031. View

18.

Zyromski N, Sandoval J, Pitt H, Ladd A, Fogel E, Mattar W . Annular pancreas: dramatic differences between children and adults. J Am Coll Surg. 2008; 206(5):1019-25. DOI: 10.1016/j.jamcollsurg.2007.12.009. View

19.

Fuchs C, Colditz G, Stampfer M, Giovannucci E, Hunter D, Rimm E . A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996; 156(19):2255-60. View

20.

Yang F, Jin C, Subedi S, Lee C, Wang Q, Jiang Y . Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Cancer Treat Rev. 2012; 38(6):566-79. DOI: 10.1016/j.ctrv.2012.02.003. View